Cervical Cancer - Market Insights, Epidemiology and Market Forecast - 2023 - United States

  • ID: 3920295
  • Drug Pipelines
  • Region: United States
  • 60 Pages
  • DelveInsight
1 of 3
“Cervical Cancer - Market Insights, Epidemiology and Market Forecast-2023 - United States” Report provides marketed drugs information of Cervical Cancer. It includes historical and forecasted epidemiology and market size of the Cervical Cancer of US for 2013-2023.We estimate that the market size of Cervical Cancer in United States is expected to grow at a Compound Annual Growth Rate of 0.68% and reach up to USD 96.28 million by 2023.The global market size of prophylaxis treatment for Cervical Cancer is expected to grow at a CAGR of 0.71% and reach up to USD 2210.9 Million by 2023.

Cervical Cancer needs to be focused more and more because it adversely affects younger women. It is the fourth most common cause of death among women. Cervical Cancer occurs due to the uncontrolled growth of healthy cells in cervix and forms cervical lesions. It spreads to other tissues such as vagina and uterus. Cervical Cancer is caused by inheritance of defects or mutation in genes. Cervical cancer is also caused due to the infection by the Human Papilloma Virus (HPV) which can infect cells on the surface of the skin and those lining the genitals, anus, mouth and throat, but not the blood or internal organs such as the heart or lungs.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by ourr team of industry experts.

Scope:
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- The Report also covers the detailed global historical and forecasted epidemiological data for United States from 2013-2023.
- It also provides Market size of Cervical Cancer for United States from 2013 and forecasted Market size to 2023.
- The report will help in developing business strategies by understanding the trends shaping and driving the United States market size of the Cervical Cancer
- Identifying patient populations in the United States Cervical Cancer market to improve product design, pricing, and launch plans.
- To understand the future market competition in United States Cervical Cancer therapeutics market, as well as prophylaxis and Insightful review of the key market drivers and barriers.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Report Introduction
Cervical Cancer Disease Overview
Types of Cervical Cancer
Staging of Cervical Cancer
Pathophysiology
Etiology
Risk Factors of Cervical Cancer
Diagnosis of Cervical Cancer
Epidemiology and Patient Population of Cervical Cancer
Assumptions and Rationale
United States (US)
Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Forecasted Incident Cases of Cervical Cancer in United States (2016-2023)
Historical Incident Cases of Cervical Cancer diagnosed by stage in United States (2013-2015)
Forecasted Incident Cases of Cervical Cancer diagnosed by stage in United States (2016-2023)
Treatment Landscape
Treatment Algorithm
Treatment by Stages
Cervical Cancer Treatment Regimens
Current Unmet Needs
Cervical Cancer Emerging therapies Market Size
a) Bevacizumab (Avastin)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Avastin Historical Market Sales 2013-2015
Cost of therapy of Avastin
Cervical Cancer Prophylaxis Treatments
a) Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Cervarix Historical Market Sales 2012-2015
Cost of therapy of Cervarix
b) Gardasil/ Gardasil
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Gardasil Historical Market Sales 2012-2015
Cost of therapy of Gardasil
Pipeline Product (Phase III)
a) Z-100 (Ancer 20)
b) Axalimogene filolisbac or AXAL (ADXS11-001)
c) Gimeracil-Oteracil-Tegafur (S-1, TS-1)
Pipeline Product Analysis
Cervical Cancer Therapeutics Market in United States
Historical market size of United States (2013-2015)
Forecasted market size of United States(2016-2023)
Cervical Cancer Prophylaxis Treatment Global
Historical Prophylaxis treatment market size (2013-2015)
Forecasted Prophylaxistreatment market size (2016-2023)
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About Us

List of Tables
Table 1: Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Table 2: Forecasted Incident Cases of Cervical Cancer in United States(2017-2023)
Table 3: Historical Incident Cases of Cervical Cancer Diagnosed by Cancer Stage (2013-2015)
Table 4: Forecasted Incident Cases of Cervical Cancer Diagnosed by Cancer Stage (2017-2023)
Table 5: Historical Cervical Cancer Therapeutics Market in United States (2013-2015)
Table 6: Forecasted Cervical Cancer Therapeutics Market in United States (2017-2023)
Table 7: Historical Cervical Cancer prophylaxis treatment global (2013-2015)
Table 8: Forecasted Cervical Cancer prophylaxis treatment global (2017-2023)

List of Figures
Figure 1: Pathophysiology of Cervical Cancer, 2017
Figure 2: Risk Factors of Cervical Cancer, 2017
Figure3: Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Figure 4: Forecasted Incident Cases of Cervical Cancer in United States(2017-2023)
Figure 5: Historical Incident Cases of Cervical Cancer Diagnosed by Cancer Stage (2013-2015)
Figure 6: Forecasted Incident Cases of Cervical Cancer Diagnosed by Cancer Stage (2017-2023)
Figure 7: Treatment Algorithm for Cervical Cancer, 2017
Figure 8: Treatment for patients with Stage IA1 of Cervical Cancer, 2017
Figure 9: Treatment for patients with Stage IA2 of Cervical Cancer, 2017
Figure 10: Treatment for patients with Stage IB1 of Cervical Cancer, 2017
Figure 11: Treatment for patients with Stage IB2 to Stage IVA of Cervical Cancer, 2017
Figure 12: Treatment for patients with Stage IVB of Cervical Cancer, 2017
Figure13: Historical Cervical Cancer Therapeutics Market in United States (2013-2015)
Figure 14: Forecasted Cervical Cancer Therapeutics Market in United States (2017-2023)
Figure15: Historical Cervical Cancer prophylaxis treatment global (2013-2015)
Figure16: Forecasted Cervical Cancer prophylaxis treatment global (2017-2023)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll